On the stock market since 2011, it operates in the world of health and science. It has 40 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 8% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $1.2M a year. A small number, but proof the product has real buyers.
There is $10.2M in the vault; even if every debt were paid off, $5.9M would remain.
A loss of $1.6M against $1.2M in annual sales.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
On our five-subject report card, ABSCF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ABSCF is a high-risk stock — not yet profitable, and its future rides on its product catching on.